Authors: Stephanie Bennett, Ross I. Berbeco, Guillaume Bort, Needa Brown, Lena Carmes, Sandrine Dufort, Michael John Lavelle, Geraldine Le Duc, Francois Lux, Toby Morris, Zeinaf Muradova, Andrea Protti, Olivier Tillement
Affiliation: University de Lyon, NH TherAGuIX, University of Massachsetts Lowell and Dana-Farber Cancer Institute Boston, Department of Radiation & Cellular Oncology, University of Chicago, University of Central Florida, Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, NH TherAguix, Universite de Lyon, Brigham and Women's Hospital, Dana-Farber Cancer Institute
Abstract Preview: Purpose: AGuIX is a theranostic Gd-based nanoparticle currently under phase-2 clinical testing where patients receive 2-3 doses at 1-week intervals prior to imaging and irradiation. AGuIX-Bi is a new ...